These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35739249)

  • 1. Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.
    Zhang W; Tang Y; Guo Y; Kong Y; Shi F; Sheng C; Wang S; Wang Q
    NPJ Precis Oncol; 2022 Jun; 6(1):46. PubMed ID: 35739249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhang W; Lin Z; Shi F; Wang Q; Kong Y; Ren Y; Lyu J; Sheng C; Li Y; Qin H; Wang S; Wang Q
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Validation of
    Li Z; Wang X; Yang Y; Shi F; Zhang W; Wang Q; Wang S
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.
    An F; Zhang W; Guo Y; Shi F; Kong Y; Tang L; Han C; Wang Q
    Aging (Albany NY); 2023 Aug; 15(15):7476-7495. PubMed ID: 37535001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Chen C; Li Y; Liu H; Liao M; Yang J; Liu J
    Heliyon; 2024 Apr; 10(7):e28356. PubMed ID: 38560204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Sun Y; Yang Q; Shen J; Wei T; Shen W; Zhang N; Luo P; Zhang J
    Front Cell Dev Biol; 2021; 9():745859. PubMed ID: 34660603
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
    Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
    Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
    Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
    Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological and clinical immunotherapy implications of
    Wang Q; Lyu J; Zhang W; Shi F; Ren Y; Mao Q; Liu Y; Li Y; Wang S
    Aging (Albany NY); 2021 Nov; 13(21):24271-24289. PubMed ID: 34747716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of FAT1 in Lung Adenocarcinoma and Its Relationship 
with Immune Cell Infiltration].
    Ding C; Zhao W; Huang H; Li Y; Zhang Z; Zhang R; Wang Y; Wu D; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):109-117. PubMed ID: 38453442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
    Long J; Wang D; Yang X; Wang A; Lin Y; Zheng M; Zhang H; Sang X; Wang H; Hu K; Zhao H
    BMC Med; 2021 Jul; 19(1):154. PubMed ID: 34284787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
    Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
    Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.